Do analysts prefer ABOS or APLM?

Acumen Pharmaceuticals presently has a consensus price target of $7.00, suggesting a potential upside of 203.03%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Acumen Pharmaceuticals is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ABOS or APLM?

Apollomics has higher revenue and earnings than Acumen Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.63 N/A Apollomics $8.50M 7.89 -$10.94M N/A N/A

Is ABOS or APLM more profitable?

Apollomics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -136.27% -81.64% Apollomics N/A N/A N/A

Do analysts prefer APLM or SRZN?

Surrozen has a consensus price target of $45.00, indicating a potential upside of 178.47%. Given Surrozen's stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Surrozen 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Which has preferable valuation and earnings, APLM or SRZN?

Apollomics has higher revenue and earnings than Surrozen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.89 -$10.94M N/A N/A Surrozen $3.48M 53.91 -$242.03M -$40.55 N/A

Is APLM or SRZN more profitable?

Apollomics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Surrozen -2,885.33% N/A -93.62%

Do analysts recommend APLM or TNXP?

Tonix Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 139.26%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tonix Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, APLM or TNXP?

Apollomics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.89 -$10.94M N/A N/A Tonix Pharmaceuticals $13.11M 13.40 -$124.02M -$12.94 N/A

Do analysts recommend APLM or PEPG?

PepGen has a consensus price target of $11.50, suggesting a potential upside of 322.79%. Given PepGen's stronger consensus rating and higher probable upside, analysts plainly believe PepGen is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better earnings and valuation, APLM or PEPG?

Apollomics has higher revenue and earnings than PepGen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.89 -$10.94M N/A N/A PepGen N/A N/A -$89.65M -$1.31 N/A

Is APLM or PEPG more profitable?

Apollomics' return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A PepGen N/A -51.01% -43.49%

Do analysts recommend APLM or CHRS?

Coherus Oncology has a consensus target price of $11.00, suggesting a potential upside of 773.02%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Coherus Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation and earnings, APLM or CHRS?

Coherus Oncology has higher revenue and earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.89 -$10.94M N/A N/A Coherus Oncology $42.17M 4.62 $168.02M -$1.03 N/A

Apollomics (APLM) Competitors

$23.06 -0.66 (-2.78%)

Closing price 09/23/2026 03:21 PM Eastern

Extended Trading

$23.06 +0.01 (+0.02%)

As of 09/23/2026 04:10 PM Eastern

Compare

APLM vs. ABOS, SRZN, TNXP, PEPG, and CHRS

Should you buy Apollomics stock or one of its competitors? Apollomics's main competitors and comparable companies include Acumen Pharmaceuticals (ABOS), Surrozen (SRZN), Tonix Pharmaceuticals (TNXP), PepGen (PEPG), and Coherus Oncology (CHRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Apollomics compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Apollomics has higher revenue and earnings than Acumen Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
Apollomics	$8.50M	7.89	-$10.94M	N/A	N/A

Acumen Pharmaceuticals presently has a consensus price target of $7.00, suggesting a potential upside of 203.03%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Acumen Pharmaceuticals is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Acumen Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

Apollomics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
Apollomics	N/A	N/A	N/A

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Acumen Pharmaceuticals had 3 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Acumen Pharmaceuticals and 0 mentions for Apollomics. Acumen Pharmaceuticals' average media sentiment score of 0.78 beat Apollomics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acumen Pharmaceuticals	Positive
Apollomics	Neutral

Summary

Acumen Pharmaceuticals beats Apollomics on 7 of the 12 factors compared between the two stocks.

How does Apollomics compare to Surrozen?

Apollomics (NASDAQ:APLM) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Apollomics has higher revenue and earnings than Surrozen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.89	-$10.94M	N/A	N/A
Surrozen	$3.48M	53.91	-$242.03M	-$40.55	N/A

Surrozen has a consensus price target of $45.00, indicating a potential upside of 178.47%. Given Surrozen's stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Surrozen had 2 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Surrozen and 0 mentions for Apollomics. Surrozen's average media sentiment score of 0.67 beat Apollomics' score of 0.00 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Neutral
Surrozen	Positive

19.1% of Apollomics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Apollomics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Surrozen	-2,885.33%	N/A	-93.62%

Apollomics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Summary

Surrozen beats Apollomics on 9 of the 14 factors compared between the two stocks.

How does Apollomics compare to Tonix Pharmaceuticals?

Apollomics (NASDAQ:APLM) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Apollomics has higher earnings, but lower revenue than Tonix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.89	-$10.94M	N/A	N/A
Tonix Pharmaceuticals	$13.11M	13.40	-$124.02M	-$12.94	N/A

Apollomics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Apollomics' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Tonix Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 139.26%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Apollomics. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 0 mentions for Apollomics. Tonix Pharmaceuticals' average media sentiment score of 0.32 beat Apollomics' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Neutral
Tonix Pharmaceuticals	Neutral

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Tonix Pharmaceuticals beats Apollomics on 10 of the 14 factors compared between the two stocks.

How does Apollomics compare to PepGen?

Apollomics (NASDAQ:APLM) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

PepGen has a consensus price target of $11.50, suggesting a potential upside of 322.79%. Given PepGen's stronger consensus rating and higher probable upside, analysts plainly believe PepGen is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Apollomics has higher revenue and earnings than PepGen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.89	-$10.94M	N/A	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

Apollomics' return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
PepGen	N/A	-51.01%	-43.49%

Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, PepGen has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market.

19.1% of Apollomics shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, PepGen had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for PepGen and 0 mentions for Apollomics. PepGen's average media sentiment score of 1.67 beat Apollomics' score of 0.00 indicating that PepGen is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Neutral
PepGen	Very Positive

Summary

PepGen beats Apollomics on 8 of the 12 factors compared between the two stocks.

How does Apollomics compare to Coherus Oncology?

Apollomics (NASDAQ:APLM) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Apollomics has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Apollomics' return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Coherus Oncology	-259.41%	-222.75%	-52.11%

Coherus Oncology has higher revenue and earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.89	-$10.94M	N/A	N/A
Coherus Oncology	$42.17M	4.62	$168.02M	-$1.03	N/A

19.1% of Apollomics shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 7.2% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Coherus Oncology had 3 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Coherus Oncology and 0 mentions for Apollomics. Coherus Oncology's average media sentiment score of 0.67 beat Apollomics' score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Neutral
Coherus Oncology	Positive

Coherus Oncology has a consensus target price of $11.00, suggesting a potential upside of 773.02%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coherus Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Coherus Oncology beats Apollomics on 9 of the 14 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$69.14M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	N/A	13.88	274.02	25.69
Price / Sales	7.89	1,311.41	633.28	76.04
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-7.98	15.30	10.44	6.32
Net Income	-$10.94M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-0.05%	-1.71%	-0.66%	0.17%
1 Month Performance	-2.83%	-6.17%	-3.16%	-3.27%
1 Year Performance	25.10%	30.64%	15.15%	5.58%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	1.1627 of 5 stars	$23.06 -2.8%	N/A	+25.1%	$69.14M	$8.50M	N/A	15	Gap Down High Trading Volume
ABOS Acumen Pharmaceuticals	3.0018 of 5 stars	$2.78 -4.0%	$7.00 +152.3%	+87.8%	$200.69M	N/A	N/A	61
SRZN Surrozen	2.5813 of 5 stars	$17.15 -3.5%	$45.00 +162.4%	+33.8%	$199.52M	$3.48M	N/A	44
TNXP Tonix Pharmaceuticals	4.1276 of 5 stars	$11.54 -0.7%	$24.50 +112.4%	-59.5%	$198.61M	$29.10M	N/A	142
PEPG PepGen	2.7642 of 5 stars	$2.87 -0.9%	$11.50 +301.4%	+39.5%	$198.43M	N/A	N/A	57	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. ABOS, SRZN, TNXP, PEPG, and CHRS

How does Apollomics compare to Acumen Pharmaceuticals?

Summary

How does Apollomics compare to Surrozen?

Summary

How does Apollomics compare to Tonix Pharmaceuticals?

Summary

How does Apollomics compare to PepGen?

Summary

How does Apollomics compare to Coherus Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. ABOS, SRZN, TNXP, PEPG, and CHRS

How does Apollomics compare to Acumen Pharmaceuticals?

Which has preferable earnings & valuation, ABOS or APLM?

Do analysts prefer ABOS or APLM?

Which has more risk and volatility, ABOS or APLM?

Is ABOS or APLM more profitable?

Do insiders and institutionals believe in ABOS or APLM?

Does the media prefer ABOS or APLM?

Summary

How does Apollomics compare to Surrozen?

Which has preferable valuation and earnings, APLM or SRZN?

Do analysts prefer APLM or SRZN?

Does the media refer more to APLM or SRZN?

Do insiders & institutionals believe in APLM or SRZN?

Is APLM or SRZN more profitable?

Which has more volatility & risk, APLM or SRZN?

Summary

How does Apollomics compare to Tonix Pharmaceuticals?

Which has stronger earnings and valuation, APLM or TNXP?

Is APLM or TNXP more profitable?

Do analysts recommend APLM or TNXP?

Which has more risk & volatility, APLM or TNXP?

Does the media favor APLM or TNXP?

Do insiders and institutionals believe in APLM or TNXP?

Summary

How does Apollomics compare to PepGen?

Do analysts recommend APLM or PEPG?

Which has better earnings and valuation, APLM or PEPG?

Is APLM or PEPG more profitable?

Which has more risk and volatility, APLM or PEPG?

Do insiders & institutionals hold more shares of APLM or PEPG?

Does the media refer more to APLM or PEPG?

Summary

How does Apollomics compare to Coherus Oncology?

Which has more risk & volatility, APLM or CHRS?

Is APLM or CHRS more profitable?

Which has higher valuation and earnings, APLM or CHRS?

Do insiders and institutionals hold more shares of APLM or CHRS?

Does the media refer more to APLM or CHRS?

Do analysts recommend APLM or CHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools